These variants increased receptor activity by biasing signalling towards β-arrestin recruitment and increased mitogen-activated protein kinase pathway signalling, indicating that drugs that preferentially activate these MC4R pathways may be effective in reducing weight and treating obesity-related disease (Lotta et al. 2019). The gene discussed is MC4R; the disease is obesity due to melanocortin 4 receptor deficiency.